PureTech Health’s subsidiary, Gallop Oncology, announced promising new data from its Phase 1b trial of LYT-200, a monoclonal antibody, in treating relapsed/refractory acute myeloid leukemia (AML). The ...
Detailed price information for Astellas Pharma Inc (ALPMF) from The Globe and Mail including charting and trades.
TipRanks on MSN
AbbVie’s AML Study Termination: Implications for Investors
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie has recently provided an update on its Phase 3 ...
Kura Oncology’s consensus analyst price target has nudged upward, rising from $27.00 to $27.18 following new coverage and insight into the company’s outlook. This minor revision signals a cautiously ...
In a significant development, Syndax Pharmaceuticals Inc. has announced a new clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With ...
New Drug Application for ziftomenib in adults with R/R NPM1 -m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 – ...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--DataVisor, a stand-out provider of AI-powered fraud and financial crime prevention solutions, has been recognized as a Leader, the report’s highest designation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback